Development of a Target Product Profile for a Proteomic Blood Test to Aid the Diagnosis of Cranial Giant Cell Arteritis - Study protocol
- 1University of Leeds
Abstract
BackgroundGiant cell arteritis (GCA) is the commonest systemic vasculitis and a medical emergency. High-dose glucocorticoids are started on suspicion, before confirmation, and cause substantial dose-dependent harm in the many patients who prove not to have GCA. Diagnostic confirmation by temporal artery biopsy or ultrasound remains imperfect. The performance of both approaches is influenced by the clinical context and, for ultrasound, operator expertise, creating the potential for both unnecessary treatment and delayed or missed diagnosis. A laboratory-based, multi-analyte proteomic blood test may help, but its intended use and performance requirements are undefined.
ObjectiveTo develop, by structured expert consensus, a Target Product Profile (TPP) for a laboratory-based, multi-analyte proteomic blood test to aid the diagnosis of cranial GCA in secondary care, used alongside clinical assessment, imaging and/or biopsy, with the primary objective of reducing unnecessary glucocorticoid exposure without increasing missed cases, from a UK health-system perspective.
Methods and analysisA multidisciplinary committee of approximately 15 to 30 members, including patient and public representatives, will follow a three-phase process: a scoping phase that confirms the intended use and the prioritised list of characteristics; a drafting phase that specifies minimum (acceptable) and preferred (desirable) values across the TPP domains, using outcome-based methods where feasible; and a consensus-building phase using an up-to-three-round modified Delphi (75% consensus threshold) with interim consensus meetings and a 28-day public consultation. Reporting follows ACCORD and CREDES.
Related
- Diagnosis and management of giant cell arteritis
- The Use of Vessel Wall Imaging for Making an Early Diagnosis of Giant Cell Arteritis in a Case with Cerebral Infarction
- Takayasu Arteritis in a Middle-aged Woman Following Prolonged Subsequent Fever after COVID-19 Infection: An Early Diagnosis Using Contrast-enhanced CT
- Positron Emission Tomography-Computed Tomography (PET-CT) Diagnosis of Large-Vessel Giant Cell Arteritis Presenting as Pyrexia of Unknown Origin Without Classical Cranial Features: A Case Report.
- Evaluating [¹⁸F]-AlF-FAPI-74 PET/CT for diagnosis of the unfavourable CMS4 colorectal cancer subtype (FoCus study): protocol for a prospective, observational, proof-of-concept clinical study.
BibTeX
@misc{morgan2026development,
title = {{Development of a Target Product Profile for a Proteomic Blood Test to Aid the Diagnosis of Cranial Giant Cell Arteritis - Study protocol}},
author = {A. W. Morgan and S. Mackie and M. W. Iles and M. Yang and P. Cocco and A. Rebane and J. Robinson and L. Sorensen and M. P. Messenger},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.07.26362451},
url = {https://www.medrxiv.org/content/10.64898/2026.09.07.26362451v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Development of a Target Product Profile for a Proteomic Blood Test to Aid the Diagnosis of Cranial Giant Cell Arteritis - Study protocol
AU - A. W. Morgan
AU - S. Mackie
AU - M. W. Iles
AU - M. Yang
AU - P. Cocco
AU - A. Rebane
AU - J. Robinson
AU - L. Sorensen
AU - M. P. Messenger
PY - 2026
DA - 2026/09/07
PB - medRxiv
DO - 10.64898/2026.09.07.26362451
UR - https://www.medrxiv.org/content/10.64898/2026.09.07.26362451v1
AB - BackgroundGiant cell arteritis (GCA) is the commonest systemic vasculitis and a medical emergency. High-dose glucocorticoids are started on suspicion, before confirmation, and cause substantial dose-dependent harm in the many patients who prove not to have GCA. Diagnostic confirmation by temporal artery biopsy or ultrasound remains imperfect. The performance of both approaches is influenced by the clinical context and, for ultrasound, operator expertise, creating the potential for both unnecessary treatment and delayed or missed diagnosis. A laboratory-based, multi-analyte proteomic blood test may help, but its intended use and performance requirements are undefined. ObjectiveTo develop, by structured expert consensus, a Target Product Profile (TPP) for a laboratory-based, multi-analyte proteomic blood test to aid the diagnosis of cranial GCA in secondary care, used alongside clinical assessment, imaging and/or biopsy, with the primary objective of reducing unnecessary glucocorticoid exposure without increasing missed cases, from a UK health-system perspective. Methods and analysisA multidisciplinary committee of approximately 15 to 30 members, including patient and public representatives, will follow a three-phase process: a scoping phase that confirms the intended use and the prioritised list of characteristics; a drafting phase that specifies minimum (acceptable) and preferred (desirable) values across the TPP domains, using outcome-based methods where feasible; and a consensus-building phase using an up-to-three-round modified Delphi (75% consensus threshold) with interim consensus meetings and a 28-day public consultation. Reporting follows ACCORD and CREDES.
ER -